$1,163.08
-1.05%
N/A-$12.33
Healthcare
Drug Manufacturers - General
NYSE
Active Trading
Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the ...
C-Suite Executives
(0)The C-suite executives form a cohesive leadership team driving the company's financial strategy and innovation.
Key Team Members
No executives available for this level
Founder / CEO
1
C-Level
8
VP
1
Board
0
Director / Board
0
Other
0
Key Executives
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
| David A. Ricks | Chairman & CEO | USD 8,921,701 | 1968 | Active | |
| Daniel Skovronsky | Chief Scientific & Product Officer and President of Lilly Research Laboratories | USD 4,898,731 | — | 1974 | Active |
| Anat Hakim | Executive Vice President, General Counsel & Secretary | USD 3,342,570 | 1969 | Active | |
| Lucas E. Montarce | Executive Vice President & Chief Financial Officer | USD 3,240,000 | 1977 | Active | |
| Jacob S. Van Naarden | Executive VP, President of Lilly Oncology & Head of Corporate Business Development | USD 2,998,730 | 1985 | Active | |
| Diogo Rau | Executive VP and Chief Information & Digital Officer | USD 1,056,809 | 1975 | Active | |
| Ilya Yuffa | Executive VP and President of Lilly USA & Global Customer Capabilities | — | 1975 | Active | |
| Eric Dozier | Executive Vice President & Chief People Officer | — | 1967 | Active | |
| Michael Czapar | Director of Investor Relations | — | — | Active | |
| Donald A. Zakrowski | Senior Vice President of Finance & Chief Accounting Officer | — | — | Active |
Executive Compensation
(deduped by latest filing date per person-year)| Filing Date | Year | Name | Position | Level | Salary | Bonus | Stock Award | Option Award | Incentive | Other | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-20 | 2025 | David A. Ricks Chair, | President President, and Chief Chief Executive Officer | Founder / CEO | $1.70M | $0 | $23.32M | $0 | $6.49M | $5.19M | $36.70M |
| 2026-03-20 | 2025 | Daniel M. Skovronsky, M.D., Ph.D. Executive | Vice Vice President President, Chief Chief Scientific and Product Officer and President President, Lilly Research Labs | C-Level | $1.49M | $0 | $12.00M | $0 | $3.25M | $1.05M | $17.79M |
| 2026-03-20 | 2025 | Anat Hakim Executive | Vice Vice President President, General General Counsel and Secretary | C-Level | $1.00M | $0 | $6.00M | $0 | $2.18M | $665.52K | $9.85M |
| 2026-03-20 | 2025 | Lucas Montarce Executive | Vice Vice President President and Chief Chief Financial Officer | C-Level | $1.00M | $0 | $5.00M | $0 | $2.18M | $303.31K | $8.48M |
| 2026-03-20 | 2025 | Jake Van Naarden Executive | Vice Vice President President and President President, Lilly Oncology and Head of Corporate Business Development | C-Level | $920.19K | $0 | $4.50M | $0 | $2.01M | $159.89K | $7.59M |
| 2026-03-20 | 2024 | David A. Ricks Chair, | President President, and Chief Chief Executive Officer | Founder / CEO | $1.69M | $0 | $19.75M | $0 | $5.71M | $2.10M | $29.24M |
| 2026-03-20 | 2024 | Daniel M. Skovronsky, M.D., Ph.D. Executive | Vice Vice President President, Chief Chief Scientific and Product Officer and President President, Lilly Research Labs | C-Level | $1.43M | $0 | $7.50M | $0 | $3.22M | $488.85K | $12.64M |
| 2026-03-20 | 2024 | Anat Hakim Executive | Vice Vice President President, General General Counsel and Secretary | C-Level | $1.00M | $0 | $3.95M | $0 | $2.25M | $278.36K | $7.48M |
| 2026-03-20 | 2024 | Jake Van Naarden Executive | Vice Vice President President and President President, Lilly Oncology and Head of Corporate Business Development | C-Level | $890.38K | $0 | $2.70M | $0 | $2.00M | $179.95K | $5.77M |
| 2025-03-21 | 2024 | Anat Ashkenazi Executive | Vice Vice President President and Chief Chief Financial Officer | C-Level | $634.04K | $0 | $3.75M | $0 | $0 | $576.92K | $4.96M |
| 2026-03-20 | 2024 | Lucas Montarce Executive | Vice Vice President President and Chief Chief Financial Officer | C-Level | $664.64K | $0 | $1.07M | $0 | $1.11M | $102.19K | $2.95M |
| 2025-03-21 | 2024 | Gordon Brooks Interim | CFO CFO and Group Vice Vice President President - Controller and Corporate Strategy | C-Level | $558.29K | $50.00K | $1.30M | $0 | $667.66K | $164.32K | $2.74M |
| 2026-03-20 | 2023 | David A. Ricks Chair, | President President, and Chief Chief Executive Officer | Founder / CEO | $1.62M | $0 | $18.84M | $0 | $4.40M | $1.70M | $26.57M |
| 2026-03-20 | 2023 | Daniel M. Skovronsky, M.D., Ph.D. Executive | Vice Vice President President, Chief Chief Scientific and Product Officer and President President, Lilly Research Labs | C-Level | $1.33M | $0 | $7.48M | $0 | $2.41M | $631.07K | $11.85M |
| 2025-03-21 | 2023 | Anat Ashkenazi Executive | Vice Vice President President and Chief Chief Financial Officer | C-Level | $1.03M | $0 | $3.69M | $0 | $1.87M | $1.01M | $7.60M |
| 2026-03-20 | 2023 | Anat Hakim Executive | Vice Vice President President, General General Counsel and Secretary | C-Level | $980.77K | $0 | $3.95M | $0 | $1.78M | $298.28K | $7.01M |
| 2026-03-20 | 2023 | Jake Van Naarden Executive | Vice Vice President President and President President, Lilly Oncology and Head of Corporate Business Development | C-Level | $830.77K | $0 | $2.42M | $0 | $1.50M | $127.86K | $4.89M |
| 2025-03-21 | 2022 | David A. Ricks Chair, | President President, and Chief Chief Executive Officer | Founder / CEO | $1.50M | $0 | $16.98M | $0 | $2.70M | $216.88K | $21.40M |
| 2025-03-21 | 2022 | Daniel M. Skovronsky, M.D., Ph.D. Executive | Vice Vice President President, Chief Chief Scientific Officer and President President, Lilly Research Laboratories and Lilly Immunology | C-Level | $1.20M | $0 | $5.75M | $0 | $1.44M | $72.11K | $8.46M |
| 2025-03-21 | 2022 | Anat Hakim Executive | Vice Vice President President, General General Counsel and Secretary | C-Level | $875.96K | $0 | $3.13M | $0 | $1.05M | $199.35K | $5.26M |
| 2025-03-21 | 2022 | Anat Ashkenazi Executive | Vice Vice President President and Chief Chief Financial Officer | C-Level | $940.38K | $0 | $3.13M | $0 | $1.13M | $56.42K | $5.26M |
| 2023-03-17 | 2022 | Patrik Jonsson Executive | Vice Vice President President and President President, Lilly Immunology, Lilly USA and Chief Chief Customer Officer | C-Level | $740.38K | $0 | $2.19M | $0 | $888.46K | $99.92K | $3.92M |
| 2025-03-21 | 2022 | Jake Van Naarden Executive | Vice Vice President President and President President, Loxo@Lilly | C-Level | $735.58K | $0 | $1.93M | $0 | $882.69K | $70.31K | $3.62M |
| 2024-03-22 | 2021 | David A. Ricks Chair, | President President, and Chief Chief Executive Officer | Founder / CEO | $1.50M | $0 | $14.97M | $0 | $2.48M | $2.57M | $21.51M |
| 2024-03-22 | 2021 | Daniel M. Skovronsky, M.D., Ph.D. Executive | Vice Vice President President, Chief Chief Scientific Officer and President President, Lilly Research Laboratories and Lilly Immunology | C-Level | $1.00M | $0 | $5.02M | $0 | $1.10M | $402.79K | $7.53M |
| 2022-03-18 | 2021 | Daniel M. Skovronsky, M.D., Ph.D. | Senior Senior Vice Vice President President, Chief Chief Scientific and Medical Officer and President President, Lilly Research Laboratories | C-Level | $1.00M | $0 | $5.02M | $0 | $1.10M | $402.79K | $7.53M |
| 2024-03-22 | 2021 | Jake Van Naarden Executive | Vice Vice President President and President President, Loxo@Lilly | C-Level | $745.65K | $218.72K | $4.10M | $0 | $1.03M | $29.37K | $6.12M |
| 2022-03-18 | 2021 | Jacob Van Naarden | Senior Senior Vice Vice President President, CEO CEO Loxo Oncology at Lilly and President President, Lilly Oncology | Founder / CEO | $745.65K | $218.72K | $4.10M | $0 | $1.03M | $29.37K | $6.12M |
| 2022-03-18 | 2021 | Diogo Rau | Senior Senior Vice Vice President President and Chief Chief Information and Digital Officer | C-Level | $412.31K | $250.00K | $4.00M | $0 | $362.83K | $76.19K | $5.10M |
| 2022-03-18 | 2021 | Anat Ashkenazi | Senior Senior Vice Vice President President and Chief Chief Financial Officer | C-Level | $850.43K | $0 | $2.45M | $0 | $907.82K | $446.36K | $4.66M |
| 2024-03-22 | 2021 | Anat Ashkenazi Executive | Vice Vice President President and Chief Chief Financial Officer | C-Level | $850.43K | $0 | $2.45M | $0 | $906.89K | $446.36K | $4.66M |
| 2024-03-22 | 2021 | Anat Hakim Executive | Vice Vice President President, General General Counsel and Secretary | C-Level | $775.00K | $0 | $2.24M | $0 | $852.50K | $145.45K | $4.02M |
| 2022-03-18 | 2021 | Joshua L. Smiley | Former Former Senior Senior Vice Vice President President and Chief Chief Financial Officer | C-Level | $230.83K | $0 | $0 | $0 | $0 | $13.85K | $244.68K |
| 2023-03-17 | 2020 | David A. Ricks Chair, | President President, and Chief Chief Executive Officer | Founder / CEO | $1.48M | $0 | $13.59M | $0 | $2.63M | $6.01M | $23.71M |
| 2021-03-19 | 2020 | David A. Ricks Chairman, | President President, and Chief Chief Executive Officer | Founder / CEO | $1.48M | $0 | $13.59M | $0 | $2.63M | $6.01M | $23.71M |
| 2023-03-17 | 2020 | Daniel M. Skovronsky, M.D., Ph.D. Executive | Vice Vice President President, Chief Chief Scientific and Medical Officer and President President, Lilly Research Laboratories | C-Level | $983.33K | $0 | $4.46M | $0 | $1.10M | $809.76K | $7.35M |
| 2022-03-18 | 2020 | Daniel M. Skovronsky, M.D., Ph.D. | Senior Senior Vice Vice President President, Chief Chief Scientific and Medical Officer and President President, Lilly Research Laboratories | C-Level | $983.33K | $0 | $4.46M | $0 | $1.10M | $809.76K | $7.35M |
| 2022-03-18 | 2020 | Joshua L. Smiley | Former Former Senior Senior Vice Vice President President and Chief Chief Financial Officer | C-Level | $983.33K | $0 | $3.59M | $0 | $0 | $2.74M | $7.31M |
| 2021-03-19 | 2020 | Alfonso G. Zulueta | Senior Senior Vice Vice President President and President President, Lilly International | C-Level | $850.00K | $0 | $2.45M | $0 | $952.85K | $2.32M | $6.57M |
| 2023-03-17 | 2020 | Anat Hakim Executive | Vice Vice President President, General General Counsel and Secretary | C-Level | $710.42K | $150.00K | $4.17M | $0 | $670.63K | $212.81K | $5.92M |
| 2021-03-19 | 2020 | Anat Hakim | Senior Senior Vice Vice President President, General General Counsel and Secretary | C-Level | $710.42K | $150.00K | $4.17M | $0 | $670.63K | $212.81K | $5.92M |
| 2022-03-18 | 2019 | David A. Ricks Chair, | President President, and Chief Chief Executive Officer | Founder / CEO | $1.40M | $0 | $12.22M | $0 | $2.92M | $4.74M | $21.28M |
| 2021-03-19 | 2019 | David A. Ricks Chairman, | President President, and Chief Chief Executive Officer | Founder / CEO | $1.40M | $0 | $12.22M | $0 | $2.92M | $4.74M | $21.28M |
| 2020-03-20 | 2019 | Michael J. Harrington (retired) | Senior Senior Vice Vice President President and General General Counsel | C-Level | $893.38K | $0 | $2.97M | $0 | $993.44K | $2.64M | $7.50M |
| 2022-03-18 | 2019 | Joshua L. Smiley | Former Former Senior Senior Vice Vice President President and Chief Chief Financial Officer | C-Level | $895.83K | $0 | $3.14M | $0 | $1.18M | $2.13M | $7.35M |
| 2020-03-20 | 2019 | Enrique A. Conterno (retired) | Senior Senior Vice Vice President President and President President, Lilly Diabetes and President President, Lilly USA | C-Level | $833.33K | $0 | $3.03M | $0 | $1.10M | $2.22M | $7.18M |
| 2022-03-18 | 2019 | Daniel M. Skovronsky, M.D., Ph.D. | Senior Senior Vice Vice President President, Chief Chief Scientific and Medical Officer and President President, Lilly Research Laboratories | C-Level | $900.00K | $0 | $4.07M | $0 | $1.19M | $500.52K | $6.66M |
| 2021-03-19 | 2018 | David A. Ricks Chairman, | President President, and Chief Chief Executive Officer | Founder / CEO | $1.40M | $0 | $10.58M | $0 | $3.63M | $1.61M | $17.23M |
| 2020-03-20 | 2018 | Michael J. Harrington (retired) | Senior Senior Vice Vice President President and General General Counsel | C-Level | $860.30K | $0 | $3.00M | $0 | $1.19M | $390.56K | $5.44M |
| 2021-03-19 | 2018 | Joshua L. Smiley | Former Former Senior Senior Vice Vice President President and Chief Chief Financial Officer | C-Level | $875.00K | $0 | $2.70M | $0 | $1.44M | $227.48K | $5.25M |
| 2021-03-19 | 2018 | Daniel M. Skovronsky, M.D., Ph.D. | Senior Senior Vice Vice President President, Chief Chief Scientific Officer, and President President, Lilly Research Laboratories | C-Level | $837.50K | $0 | $2.81M | $0 | $1.38M | $125.97K | $5.15M |
| 2020-03-20 | 2018 | Enrique A. Conterno (retired) | Senior Senior Vice Vice President President and President President, Lilly Diabetes and President President, Lilly USA | C-Level | $794.68K | $0 | $3.06M | $0 | $1.10M | $47.68K | $5.00M |
| 2019-03-22 | 2018 | Enrique A. Conterno | Senior Senior Vice Vice President President and President President, Lilly Diabetes and President President, Lilly USA | C-Level | $794.68K | $0 | $3.06M | $0 | $1.10M | $47.68K | $5.00M |
| 2020-03-20 | 2017 | David A. Ricks Chairman, | President President, and Chief Chief Executive Officer | Founder / CEO | $1.40M | $0 | $10.20M | $0 | $2.81M | $1.43M | $15.85M |
| 2020-03-20 | 2017 | Enrique A. Conterno (retired) | Senior Senior Vice Vice President President and President President, Lilly Diabetes and President President, Lilly USA | C-Level | $762.00K | $0 | $6.00M | $0 | $816.87K | $1.05M | $8.62M |
| 2020-03-20 | 2017 | Michael J. Harrington (retired) | Senior Senior Vice Vice President President and General General Counsel | C-Level | $856.13K | $0 | $2.76M | $0 | $917.77K | $1.71M | $6.24M |
| 2019-03-22 | 2017 | Michael J. Harrington | Senior Senior Vice Vice President President and General General Counsel | C-Level | $856.13K | $0 | $2.76M | $0 | $917.77K | $1.71M | $6.24M |
| 2019-03-22 | 2016 | Michael J. Harrington | Senior Senior Vice Vice President President and General General Counsel | C-Level | $827.40K | $0 | $2.30M | $0 | $774.45K | $1.49M | $5.39M |
Total Compensation Trend
Sum of disclosed compensation by year (USD million)
Key Roles Compensation Lines
Top founder/C-level executives over time (USD million)